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Since early December 2019 when the first pneumonia 
cases of unknown origin were identified in Wuhan, the 
COVID-19 outbreak has been expanding from Wuhan 
throughout China, being exported to a growing number 
of countries Worldwide (1). In the absence of any 
specific therapeutic drug approach, one of the hypothesis 
catching the attention is the involvement of angiotensin-
converting enzyme-2 (ACE2) cascade. ACE2 is a 
monocarboxypeptidase that cleaves away (i) 
phenylalanine from angiotensin (ANG) II, converting it 
to ANG-(1-7), and (ii) leucine from ANG I, converting 
it to ANG-(1-9) (figure 1).  Altogether, ACE2, ANG-(1-
9), and ANG-(1-7) negatively regulate the renin-
angiotensin system (RAS), one of the most potent 
cardiovascular regulator and an important target for 
therapeutic drugs (2). Specifically, Ang 1-7 is a major 
component of the counter-regulatory axis of the RAS (3) 
and Ang 1-9 becomes relevant during ACE inhibition, 
since Ang I is abundantly present after treatment with 
RAS inhibitors and might determine an increase of Ang 
1-9 (4). ACE2, which possesses also noncatalytic 
functions, has been described as the receptor for both 
two known coronavirus, i.e. the SARS-coronavirus 
(SARS-CoV) and the human respiratory coronavirus 
NL63 (5). ACE2 could be considered the host receptor 
for the novel coronavirus 2019-nCoV/SARS-CoV-2. 
Patients with diabetes mellitus and/or arterial 
hypertension under treatment with ACE-inhibitors 
(ACE-i) or angiotensin II type-I receptor blockers 
(ARBs) present with increased expression of ACE2 (6). 
Both of these diseases are strong risk factors for severe 
SARS-CoV-2 related disease. Thus, it should be 
prioritized investigations aimed at unraveling if 
morbidities SARS-CoV-2 related are influenced by 
current ACE-i/ARBs treatment. In this complex scenario 
and in the absence of effective therapies for COVID-19, 
public health relies on the identification of vulnerable 
(high-risk) populations based on clinical history or risk 
factors.  In this view, smoke, a causative agent of 
pulmonary illnesses through its action on nicotinic 
receptors, is also significantly associated with high 
mortality rates in infections of various respiratory 
viruses including those that underlie annual (seasonal) 
influenza. Although smoking is associated to a rise in 
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ACE2 expression in the lung, active smoking does not 
seem significantly associated with a raised risk of 
progressing towards severe disease in COVID-19 (OR, 
1.69; 95% CI, 0.41–6.92; p=0.254) (7). Conversely, it is 
worth mentioning that the activation of nicotinic 
receptors can directly impact the putative receptor for 
the virus (ACE2) leading to deleterious inflammatory 
signaling in lung epithelial cells, i.e. JAK/STAT 
pathway (8).The basal expression pattern of human 
ACE2 among ethnicities might be critical for the 
susceptibility, symptoms, and outcomes of 2019-
nCoV/SARS-CoV-2 infection. In this perspective, East 
Asian populations have much higher ACE2 expression 
than white and African-American donors, although, in 
lung tissues from Asian and Caucasian populations, no 
significant differences were found (9). Considering that 
Black subjects show a high frequency of variants of 
candidate genes associated with low renin-resistant 
hypertension, it could be of interest to understand if 
hypertension in African-descent populations contributes 
to an imbalance in the activities of the ACE2/Ang-(1-
7)/Mas and the ACE/Ang II/AT1 axes (10). In Africa, as 
of 31st March 2020, the WHO web site (11) reports a 
case fatality ratio of 2.4% among a cumulative total of 
3671 confirmed cases across 41 countries in the region. 
Taking into account the different health system when 
compared to European region, mortality appears lower 
in the African one. Notably, despite distribution of 
ethnicity is not available, South Africa, the richest and 
the most developed country in the African region, shows 
the higher incidence of infection (1353 infected subjects) 
with only 5 deaths reported (rate 0.4%). Conversely, 
Algeria (Northern country) with 99% of population 
composed by Arabian or Berber ethnicities, has faced 
584 infections with 35 recorded fatal events (rate 6%). 
Thus, this trend may be extremely interesting if 
confirmed. Finally, although COVID-19 cases were rare 
in infants and newborns, nine hospitalized infants 
diagnosed with COVID-19 in China from 8th December 
2019 to 6th February 2020, were reported. Less than 1% 
of the cases were children younger than 10 years of age 
and most of them presented a milder clinical course. 
Interestingly, although epidemiology of acute 
respiratory distress syndrome showed no differences in 
activity of ACE and ACE2 between children and adults, 
markers involving the neutrophil response (MPO, IL-6, 
and IL-10) were significantly lower in neonates/children 
compared to adults/older adults (12). 
Overall, as recently reported ACE2 could be a “double-
edged sword” turning off the renin-angiotensin system 
and leading to beneficial effects but also mediates 
unique susceptibility to lung and cardiovascular disease 
in COVID-19 patients by acting as the SARS-CoV-2 
receptor (13). An answer to this hypothesis, will 
probably come from an open label, randomized 
controlled trial evaluating the safety and efficacy of 
recombinant human ACE2 as a treatment for COVID-19 
patients (NCT04287686) (14). 
Figure 1. The enzymatic cascade that involves the renin-
angiotensin system has been depicted along with key 
receptor systems and biological effects.   
ACE,angiotensin-converting enzyme; Ang, angiotensin; 
ATR, Angiotensin receptor. 
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